Navigation Links
Drugs targeting chromosomal instability may fight a particular breast cancer subtype
Date:2/6/2012

PHILADELPHIA -- Another layer in breast cancer genetics has been peeled back.

A team of researchers at Jefferson's Kimmel Cancer Center (KCC) led by Richard G. Pestell, M.D., PhD., FACP, Director of the KCC and Chair of the Department of Cancer Biology, have shown in a study published online Feb. 6 in the Journal of Clinical Investigation that the oncogene cyclin D1 may promote a genetic breakdown known as chromosomal instability (CIN). CIN is a known, yet poorly understood culprit in tumor progression.

The researchers used various in vitro and in vivo model systems to show that elevated levels of cyclin D1 promotes CIN and correlate with CIN in the luminal B breast cancer subtype. Cyclin D1 protein is elevated in breast, prostate, lung and gastrointestinal malignancies.

The findings suggest that shifting towards drugs targeting CIN may improve outcomes for patients diagnosed with luminal B subtype. Luminal B breast cancer has high proliferation rates and is considered a high grade malignancy.

Estrogen or progesterone receptor positive and HER2 positive cancers indicate luminal B, and about 10 percent of patients are diagnosed with it every year, though many do not respond well to treatment. The identification of CIN in luminal B provides a new therapeutic opportunity for these patients.

"Cyclin D1 has a well defined role in cell proliferation through promoting DNA replication," says Dr. Pestell. "My team was the first to discover that cyclin D1 also has alternate functions, which include regulating gene transcription at the level of DNA. We were interested in discovering the function of DNA associated cyclin D1."

To help answer this, the researchers, including lead author Mathew C. Casimiro, Ph.D., of the Department of Cancer Biology at Thomas Jefferson University, first needed to directly access cyclin D1's role in gene regulation.

They applied an analysis known as ChIP sequencing to study the protein's interactions with genes that comprise the entire mouse genome, and found it occupied the regulatory region of genes governing chromosomal stability with high incidence.

They went on to show cyclin D1 promoted aneuploidy and chromosomal rearrangements typically found in cancers.

Faulty chromosomeseither too many or too few, or even ones that are the wrong shape or sizehave been shown to be the crux of many cancers. However, a major question of cancer genetics is the mechanisms of CIN. What causes the breakdown in chromosomal stability?

As cyclin D1 expression is increased in the early phases of tumorigenesis, cyclin D1 may be an important inducer of CIN in tumors.

To analyze the association between CIN and cyclin D1 expression in the context of breast cancer, the team aligned an expression of a 70-gene set with the highest CIN score against over 2,000 breast cancer samples. They stratified the samples based on previously described subtypes and aligned them with cyclin D1 expression profiled across the dataset.

A significant correlation among CIN, cyclin D1 and the luminal B subtype was identified, and it was apparent that the relationship between these levels was subtype specific.

"Interestingly, previous studies have presented contradictory results," Dr. Pestell says. "Many studies have suggested a positive correlation between cyclin D1 expression and outcomes, while others have shown reduced survival. Here, we've dug deep, using a genome-wide analysis, and found that overexpression of the protein appears to be directly associated with the genes involved in CIN and this correlates with the luminal B subtype."

Drugs targeting chromosomal instability for cancer therapy have been explored, but a sub-stratification rationale for the luminal B subtype has not been established. The research presented in this study suggests such a target is worthy of further investigation.

"There is a big drive towards using targeting therapies for stratified breast cancers," says Dr. Casimiro. "What we are thinking is that there are a growing number of drugs that target aneuploidy, like AICAR and 17-AAG, that may be used as an adjuvant therapy in patients with luminal B breast cancer."


'/>"/>
Contact: Steve Graff
stephen.graff@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert  

Related medicine news :

1. Websites advertising cholesterol-lowering drugs of poor quality
2. Many children with liver transplants from parents can safely stop using anti-rejection drugs
3. Heartburn Drugs May Raise Fracture Risk in Older Women
4. Experimental Drugs Do Battle Against Advanced Prostate Cancer
5. NIH launches trials to evaluate CPR and drugs after sudden cardiac arrest
6. UC Davis researchers refine nanoparticles for more accurate delivery of cancer drugs
7. Researchers study how chemicals in drugs and around us impact stem cells
8. Counterfeit and substandard anti-malaria drugs threaten crisis in Africa, experts warn
9. Combining 2 anti-HER2 drugs may provide better preoperative breast cancer treatment
10. 1 in 10 Canadians cannot afford prescription drugs: UBC study
11. Certain Diabetes Drugs Might Aid Weight Loss
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drugs targeting chromosomal instability may fight a particular breast cancer subtype
(Date:8/17/2017)... ... 2017 , ... An August 2 article on NextShark discusses a ... influenced by the growing popularity of “pretty boys” in both K-Pop and television K-Drama. ... male appearance are changing not only in the Asian nation, where plastic surgery has ...
(Date:8/17/2017)... ... 2017 , ... Pot Valet is a leading provider of premium medical-grade cannabis ... state, and soon, every state in the country, the company offers patients safe, legal, ... altogether. , According to Pot Valet, all California patients have the legal ...
(Date:8/17/2017)... ... August 17, 2017 , ... A recent report indicates that ... industry in 2016 cited deficiencies in data integrity. The FDA outlines their expectations for ... , Presented as part of the Beckman Coulter Life Sciences Virtual Trade ...
(Date:8/16/2017)... ... August 16, 2017 , ... An August 3rd article on Reuters covers ... of a report in JAMA (the Journal of the American Medical Association). The study found ... to achieve BMIs under 30, when compared to patients with lower BMIs. At present, weight ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... is collaborating with a New England student to educate the public on the ... in 2016 for launching the first-ever National Concussion Awareness Day. , Brooke is ...
Breaking Medicine News(10 mins):
(Date:8/10/2017)... Rehabilitation Network (PRN), acquired the long-standing outpatient rehabilitation clinic, Belmar ... The reputable clinic will continue to be co-owned and managed ... of four clinicians. Lipkin received his doctorate in physical therapy ... of experience with a strong background in manual therapy. ... clinic in and around the Denver ...
(Date:8/7/2017)... WARSAW, Ind. , Aug. 7, 2017 Zimmer ... in musculoskeletal healthcare, today announced that its Board of Directors ... stockholders for the third quarter of 2017. ... will be paid on or about October 27, 2017 to ... September 22, 2017.  Future declarations of dividends are subject to ...
(Date:8/4/2017)... , Aug. 4, 2017 The search ... shortly after a physician/patient consult has long been the ... was a notable focus of the largest meeting of ... according to healthcare market research firm Kalorama Information.  The ... testing (POCT) offerings or related supplies and software were ...
Breaking Medicine Technology: